An­oth­er mega-start­up: Chi­na in­vestors back TCR2's $125M cash round to fu­el a pre­clin­i­cal as­sault on sol­id tu­mors

Gar­ry Men­zel

In yet an­oth­er dis­play of biotech’s bold fundrais­ing en­vi­ron­ment right now, a Cam­bridge, MA-based start­up with a hand­ful of pre­clin­i­cal can­cer drugs in its pipeline has scored a $125 mil­lion mega-round — with all of the cash in the bank.

TCR2 Ther­a­peu­tics tells me they want­ed flex­i­bil­i­ty to pur­sue “mul­ti­ple pro­grams in mul­ti­ple for­mats,” which re­quires a sig­nif­i­cant amount of cash on hand. When peo­ple get hyped about mega-rounds, sober­ing re­al­ists will al­ways point out how mega-rounds are usu­al­ly tranched. That means the cash is gat­ed, and ac­cess to that cash is de­pen­dent on the start­up meet­ing cer­tain mile­stones.

This arrange­ment pro­vides some pro­tec­tion for cau­tious in­vestors, and is com­mon­place con­sid­er­ing this in­dus­try’s fail­ure rate. In­vestors in this case, how­ev­er, ap­pear to have thrown that cau­tion to the wind, bank­ing on TCR2’s abil­i­ty to pro­vide a re­turn one way or an­oth­er.

“All the mon­ey ar­rives in the bank on day one,” said Gar­ry Men­zel, CEO at TCR2.

How did the com­pa­ny get so much cash to play with? In part, they tapped flush in­vestor groups in Chi­na, one com­po­nent of a an in­creas­ing­ly pop­u­lar strate­gic move to fo­cus heav­i­ly in that mar­ket.

“There’s so much ac­tiv­i­ty in Chi­na right now,” Men­zel said. “There’s a tremen­dous amount of clin­i­cal ex­pe­ri­ence, good man­u­fac­tur­ing ca­pa­bil­i­ties, and it’s a big mar­ket.”

The mega-round was co-led by Shang­hai-based 6 Di­men­sions Cap­i­tal and Dal­las-based Cu­ra­tive Ven­tures. A long (long) list of new in­vestors and ex­ist­ing in­vestors joined in, in­clud­ing MPM Cap­i­tal (a ma­jor in­vestor in the on­col­o­gy space). Check out the com­pa­ny’s press re­lease for the full run­down.

Patrick Baeuer­le

What has these in­vestors so jazzed? TCR2 thinks it can lever­age the com­pa­ny’s un­der­stand­ing of the T cell re­cep­tor struc­ture to im­prove on how the body’s can­cer-fight­ing cells re­spond to dis­ease. The hope is to break down bar­ri­ers that have lim­it­ed ef­fi­ca­cy, ex­tend­ing im­muno-on­col­o­gy’s range in­to sol­id tu­mors.

The com­pa­ny was found­ed in 2015 by can­cer im­mu­nol­o­gist Patrick Baeuer­le, man­ag­ing di­rec­tor of MPM Cap­i­tal. You might rec­og­nize Baeuer­le as the for­mer CSO of Mi­cromet, which used an an­ti­body to redi­rect killer T cells to de­stroy tu­mor cells. Am­gen went on to ac­quire Mi­cromet in 2012 in a deal val­ued at $1 bil­lion-plus, bring­ing Baeuer­le on board to Am­gen to con­tin­ue work­ing on Blin­cy­to, an an­ti­body-based leukemia drug.

Now Baeuer­le sits on the board of TCR2, a com­pa­ny that wants to take im­muno-on­col­o­gy far past where CAR-Ts can go.

“There’s a lot of ex­cite­ment around CAR-T, and a lot of com­pa­nies in that space,” Men­zel said. “But CAR-T ran in­to a brick wall with sol­id tu­mors. There’s just been no ac­tiv­i­ty there.”

TCR² takes its name from T cell re­cep­tors (TCR), mol­e­cules on the sur­faces of im­mune cells that rec­og­nize a spe­cif­ic mol­e­c­u­lar tar­get, or anti­gen, and fo­cus an im­mune at­tack on cells with that tar­get. But CAR-T on­ly taps a part of a TCR’s full struc­ture.

“You can think of CAR-T as a piece of the TCR,” Men­zel said. “TCR has six sub­units, and CAR-T is one.”

Al­fon­so Quin­tás Car­dama

TCR² hopes to find a way to em­ploy the full TCR — a goal that com­pa­nies like blue­bird bio, Kite (Gilead), and GSK all have their eye on.  But TCR²’s CMO Al­fon­so Quin­tás Car­dama says the start­up has a game-chang­ing dif­fer­en­tia­tor. “We are ag­nos­tic to HLA. That’s the ad­van­tage of our plat­form over any oth­er TCR plat­form that re­quires spe­cif­ic HLA geno­typ­ing.”

TCR² has four pro­grams in the pipeline, all of which are tar­get­ing can­cers. Its lead in­ves­ti­ga­tion­al drug is called TC-210, a pre­clin­i­cal sol­id tu­mor ther­a­py that tar­gets mesothe­lin, an anti­gen present in sev­er­al types of can­cer. The com­pa­ny is hop­ing that drug can be used against ovar­i­an can­cer, mesothe­lioma, cholan­gio­car­ci­no­ma, and non-small cell lung can­cer (NSCLC).

Its sec­ond pro­gram is ba­si­cal­ly TC-210 with a PD1 switch at­tached, which the com­pa­ny hopes will make the ther­a­py more ef­fec­tive in lung can­cer pa­tients.

Its re­main­ing two pro­grams are still very ear­ly in their de­vel­op­ment, in ei­ther lead op­ti­miza­tion or dis­cov­ery stage. And TCR² isn’t say­ing much about ei­ther pro­gram, ex­cept that one is called Pro­gram X and the oth­er will take on blood can­cers.

Men­zel said the mas­sive Se­ries B round will like­ly take two pro­grams to proof-of-con­cept by 2021 and fi­nance an ex­pan­sion of the plat­form. TCR² plans to dou­ble its staff over the next year — from 30 to rough­ly 60 em­ploy­ees — all of whom will be work­ing out of a brand new fa­cil­i­ty in the heart of Kendall Square.

“You’ll see us grow­ing quite rapid­ly over the next year,” Men­zel says.

With $125 mil­lion in the bank, we wouldn’t ex­pect any less.

Mer­ck is tak­ing the ax to its US op­er­a­tions, cut­ting 500 jobs in its lat­est re­or­ga­ni­za­tion

Merck is cutting 500 jobs in its US sales and headquarters commercial teams in its latest effort to find new ways to streamline the operation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Alice Shaw, Lung Cancer Foundation of America

Top ALK ex­pert and can­cer drug re­searcher Al­ice Shaw bids adieu to acad­e­mia, hel­lo to No­var­tis

Jay Bradner has recruited a marquee oncology drug researcher into the ranks of the Novartis Institutes for BioMedical Research. Alice Shaw is jumping from prestigious posts intertwined through Mass General, Harvard and Dana-Farber to take the lead of NIBR’s translational clinical oncology group.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

If you’re a big KRAS G12C fan, mark your calendars for October 28 at 4:20 pm EDT.

That’s when Mirati $MRTX will unveil its first peek at the early clinical data available on MRTX849 in presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Mirati has been experiencing the full effect of a rival’s initial success at targeting the G12C pocket found on KRAS, offering the biotech some support on the concept they’re after — and biotech fans a race to the top. Amgen made a big splash with its first positive snapshot on lung cancer, but deflated sky-high expectations as it proved harder to find similar benefits in other types of cancers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron, GSK's president of R&D and CSO, speaks to Endpoints News founder and editor John Carroll in London at Endpoints' #UKBIO19 summit on October 8, 2019

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

Last week I had a chance to sit down with Hal Barron at Endpoints’ #UKBIO19 summit to discuss his views on R&D at GSK, a topic that has been central to his life since he took the top research post close to 2 years ago. During the conversation, Barron talked about changing the culture at GSK, a move that involves several new approaches — one of which involves celebrating their setbacks as they shift resources to the most promising programs in the pipeline. Barron also discussed his new alliances in the Bay Area — including his collaboration pact with Lyell, which we covered here — frankly assesses the pluses and minuses of the UK drug development scene, and talks about his plans for making GSK a much more effective drug developer.

This is one discussion you won’t want to miss. Insider and Enterprise subscribers can log-in to watch the video.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Flu Virus (Source: CDC)

FDA ex­pands Xofluza ap­proval as Roche strug­gles to catch loom­ing flu mar­ket

As a potentially powerful flu season looms, so does a big test for Roche and its new flu drug, Xofluza. The Swiss giant just got a small boost in advance of that test as the FDA expanded Xofluza’s indication to include patients at high risk of developing flu-related complications.

Xofluza (baloxavir marboxil) was approved last October in the US, the first landmark flu drug approval in 20 years and a much-needed green light for a company that had watched its leading flu drug Tamiflu get eaten alive by generics. Like its predecessor, the pill offered a reduction in flu symptoms but not a cure.

EMA backs sev­en ther­a­pies, in­clud­ing Mer­ck­'s Ebo­la vac­cine

The first-ever Ebola vaccine is on the precipice of approval after the European Medicine’s Agency (EMA) backed the Merck product in this week’s roster of recommendations.

The drugmaker $MRK began developing the vaccine, christened Ervebo, during the West African outbreak that occurred between 2014 and 2016, killing more than 11,000.

The current outbreak in the Democratic Republic of Congo (DRC) has shown case fatality rates of approximately 67%, the agency estimated. Earlier this year, the WHO declared the outbreak — which so far has infected more than 3,000 people — a public health emergency of international concern.

Ronald Herb­st fol­lows Med­Im­mune ex­o­dus to Pyx­is CSO post; Jeff God­dard to suc­ceed CEO of AIT Bio­science

→ The outflow of top execs from MedImmune continues to fill the leadership ranks of smaller biotechs. The latest to take off is Ronald Herbst, the head of oncology research, who’s assuming the CSO post at Pyxis Oncology.  

Herbst was part of the old MedImmune organization AstraZeneca CEO Pascal Soriot restructured earlier this year, reorganizing the company and eliminating the storied subsidiary as a separate organization.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

Medical animation has in recent years become an increasingly important tool for conveying niche information to a varied audience, particularly to those audiences without expertise in the specialist area. Science programmes today, for example, have moved from the piece-to-camera of the university professor explaining how a complex disease mechanism works, to actually showing the viewer first-hand what it might look like to shrink ourselves down to the size of an ant’s foot, and travel inside the human body to witness these processes in action. Effectively communicating a complex disease pathophysiology, or the novel mechanism of action of a new drug, can be complex. This is especially difficult when the audience domain knowledge is limited or non-existent. Medical animation can help with this communication challenge in several ways.
Improved accessibility to visualisation
Visualisation is a core component of our ability to understand a concept. Ask 10 people to visualise an apple, and each will come up with a slightly different image, some apples smaller than others, some more round, some with bites taken. Acceptable, you say, we can move on to the next part of the story. Now ask 10 people to visualise how HIV’s capsid protein gets arranged into the hexamers and pentamers that form the viral capsid that holds HIV’s genetic material. This request may pose a challenge even to someone with some virology knowledge, and it is that inability to effectively visualise what is going on that holds us back from fully understanding the rest of the story. So how does medical animation help us to overcome this visualisation challenge?

UP­DAT­ED: J&J's Xarel­to, Amar­in's Vas­cepa are cost-ef­fec­tive, not bud­get friend­ly — ICER

ICER, an increasingly influential cost-effectiveness watchdog in the United States, has concluded in its review of treatments for cardiovascular disease that while the cost of J&J’s Xarelto and Amarin’s Vascepa meet its benchmark for value pricing — the two treatments will not likely treat as many patients as hoped without surpassing the annual budget threshold calculated by ICER for each therapy.